Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INHAL-102
- Development stage
- Preclinical
- Lead developer
- Inhalis Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
INHAL-102 is an investigational inhaled formulation of the folate antimetabolite **pemetrexed**, currently in the discovery stage of development by Inhalis Therapeutics SA. It is being developed for the localized treatment of neoplasms, specifically lung cancer and non-small cell lung cancer (NSCLC), as well as other respiratory diseases. By utilizing a proprietary inhalation delivery platform, INHAL-102 is designed to deliver high concentrations of the cytotoxic agent directly to the tumor site in the lungs. This approach aims to enhance therapeutic efficacy while minimizing systemic exposure and the associated toxicities typically observed with intravenous administration. Pemetrexed, the active ingredient, exerts its effect by inhibiting multiple folate-dependent enzymes essential for DNA and RNA synthesis, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).
- Other names
- Inhaled pemetrexed
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on INHAL-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INHAL-102.